Sodium valproate combined with levetiracetam in pediatric epilepsy and its influence on NSE, IL‑6, hs‑CRP and electroencephalogram improvement

Liu,Zhaoyang; Li,Jianmu; Yang,Fan; Hu,Yongbo; Liu,Jun; Hu,Hongmei; Su,Wenbing

doi:10.3892/etm.2020.8916

Sodium valproate combined with levetiracetam in pediatric epilepsy and its influence on NSE, IL‑6, hs‑CRP and electroencephalogram improvement

Authors:
- Zhaoyang Liu
- Jianmu Li
- Fan Yang
- Yongbo Hu
- Jun Liu
- Hongmei Hu
- Wenbing Su
View Affiliations

Affiliations: Department of Pediatrics, Xiantao First People's Hospital Affiliated to Yangtze University, Xiantao, Hubei 433000, P.R. China, Department of Gastrointestinal Surgery, Xiantao First People's Hospital Affiliated to Yangtze University, Xiantao, Hubei 433000, P.R. China, Department of Oncology, Xiantao First People's Hospital Affiliated to Yangtze University, Xiantao, Hubei 433000, P.R. China, Department of Ophthalmology, Xiantao First People's Hospital Affiliated to Yangtze University, Xiantao, Hubei 433000, P.R. China, Department of Gastrointestinal Medicine, Xiantao First People's Hospital Affiliated to Yangtze University, Xiantao, Hubei 433000, P.R. China
Published online on: June 19, 2020 https://doi.org/10.3892/etm.2020.8916
Pages: 2043-2048
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Efficacy of sodium valproate combined with levetiracetam (LEV) in pediatric epilepsy and its influence on neuron‑specific enolase (NSE), interleukin‑6 (IL‑6) and high‑sensitivity C‑reactive protein (hs‑CRP) as well as electroencephalogram (EEG) improvement were studied. Patients (n=100) with pediatric epilepsy admitted to and treated in Xiantao First People's Hospital Affiliated to Yangtze University from December 2015 to 2018 were enrolled in this study and randomly divided into observation group (n=50) and control group (n=50). Sodium valproate was administered in the control group, and the treatment with LEV was combined with sodium valproate in the observation group. After 12 weeks the cognitive function of patients was assessed using the Mini‑Mental State Examination (MMSE) scale, Montreal cognitive assessment (MoCA) scale and Wechsler Memory Scale‑Revised in China (WMS‑RC). The quality of life (QOL) of patients was evaluated with the QOL in epilepsy‑31 inventory (QOLIE‑31) scale and Barthel Index, and blood was drawn from the patients to detect the neurological function indicators [NSE and glial fibrillary acidic protein (GFAP)] and inflammatory indicators (IL‑6, IL‑2 and hs‑CRP). After treatment, the incidence rates of adverse reactions notably declined in the observation group (P<0.05), and the improvement in the cognitive function in the observation group were both superior to those in the control group (P<0.05). Observation group had lowered content of NSE, GFAP, IL‑6, hs‑CRP and IL‑2 (P<0.05), and α wave was markedly decreased, but θ and δ waves were notably increased in the observation group (P<0.05). In the treatment of pediatric epilepsy, sodium valproate combined with LEV produces better efficacy, fewer adverse reactions, significantly improves patients' QOL and notably lowers the content of NSE, IL‑6 and hs‑CRP with notable EEG improvement, so it is a safe and reliable treatment that is worth popularization.

View Figures

View References

1	Stafstrom CE, Moshé SL, Swann JW, Nehlig A, Jacobs MP and Schwartzkroin PA: Models of pediatric epilepsies: Strategies and opportunities. Epilepsia. 47:1407–1414. 2006.PubMed/NCBI View Article : Google Scholar
2	Harvey AS, Cross JH, Shinnar S and Mathern GW: ILAE Pediatric Epilepsy Surgery Survey Taskforce: Defining the spectrum of international practice in pediatric epilepsy surgery patients. Epilepsia. 49:146–155. 2008.PubMed/NCBI View Article : Google Scholar
3	Ettinger AB, Weisbrot DM, Nolan EE, Gadow KD, Vitale SA, Andriola MR, Lenn NJ, Novak GP and Hermann BP: Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia. 39:595–599. 1998.PubMed/NCBI
4	Becker AJ, Blümcke I, Urbach H, Hans V and Majores M: Molecular neuropathology of epilepsy-associated glioneuronal malformations. J Neuropathol Exp Neurol. 65:99–108. 2006.PubMed/NCBI View Article : Google Scholar
5	Cross JH, Jayakar P, Nordli D, Delalande O, Duchowny M, Wieser HG, Guerrini R and Mathern GW: International League against Epilepsy Subcommission for Paediatric Epilepsy Surgery; Commissions of Neurosurgery and Paediatrics: Proposed criteria for referral and evaluation of children for epilepsy surgery: Recommendations of the Subcommission for Pediatric Epilepsy Surgery. Epilepsia. 47:952–959. 2006.PubMed/NCBI View Article : Google Scholar
6	Rutter M, Graham P and Yule WA: A neuropsychiatric study in childhood. Arch Dis Child. 46(577)1971.
7	Hoare P: The development of psychiatric disorder among schoolchildren with epilepsy. Dev Med Child Neurol. 26:3–13. 1984.PubMed/NCBI View Article : Google Scholar
8	Ackers R, Besag FM, Wade A, Murray ML and Wong IC: Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Arch Dis Child. 94:443–447. 2009.PubMed/NCBI View Article : Google Scholar
9	Vigevano F: Levetiracetam in pediatrics. J Child Neurol. 20:87–93. 2005.PubMed/NCBI View Article : Google Scholar
10	De Smedt T, Raedt R, Vonck K and Boon P: Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 13:57–78. 2007.PubMed/NCBI View Article : Google Scholar
11	Wen X, Meador KJ and Hartzema A: Antiepileptic drug use by pregnant women enrolled in Florida Medicaid. Neurology. 84:944–950. 2015.PubMed/NCBI View Article : Google Scholar
12	Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, García-Fiñana M, Gummery A, Kneen R, Loring DW, Mawer G, et al: Liverpool and Manchester Neurodevelopment Group: IQ at 6 years after in utero exposure to antiepileptic drugs: A controlled cohort study. Neurology. 84:382–390. 2015.PubMed/NCBI View Article : Google Scholar
13	Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ and Craig J: Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 77:193–198. 2006.PubMed/NCBI View Article : Google Scholar
14	Rosenow F and Lüders H: Presurgical evaluation of epilepsy. Brain. 124:1683–1700. 2001.PubMed/NCBI View Article : Google Scholar
15	Tao JX, Ray A, Hawes-Ebersole S and Ebersole JS: Intracranial EEG substrates of scalp EEG interictal spikes. Epilepsia. 46:669–676. 2005.PubMed/NCBI View Article : Google Scholar
16	Goldlust IS, Hermetz KE, Catalano LM, Barfield RT, Cozad R, Wynn G, Ozdemir AC, Conneely KN, Mulle JG, Dharamrup S, et al: Unique Rare Chromosome Disorder Support Group: Mouse model implicates GNB3 duplication in a childhood obesity syndrome. Proc Natl Acad Sci USA. 110:14990–14994. 2013.PubMed/NCBI View Article : Google Scholar
17	Sakkalis V, Doru Giurc Neanu C, Xanthopoulos P, Zervakis ME, Tsiaras V, Yang Y, Karakonstantaki E and Micheloyannis S: Assessment of linear and nonlinear synchronization measures for analyzing EEG in a mild epileptic paradigm. IEEE Trans Inf Technol Biomed. 13:433–441. 2009.PubMed/NCBI View Article : Google Scholar
18	Bromley RL, Calderbank R, Cheyne CP, Rooney C, Trayner P, Clayton-Smith J, García-Fiñana M, Irwin B, Morrow JI, Shallcross R, et al: UK Epilepsy and Pregnancy Register: Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 87:1943–1953. 2016.PubMed/NCBI View Article : Google Scholar
19	Tumay Y, Altun Y, Ekmekci K and Ozkul Y: The effects of levetiracetam, carbamazepine, and sodium valproate on P100 and P300 in epileptic patients. Clin Neuropharmacol. 36:55–58. 2013.PubMed/NCBI View Article : Google Scholar
20	Akcan A, Akyildiz H, Deneme MA, Akgun H and Aritas Y: Granulomatous lobular mastitis: A complex diagnostic and therapeutic problem. World J Surg. 30:1403–1409. 2006.PubMed/NCBI View Article : Google Scholar
21	Takeda K, Sawamura S, Tamai H, Sekiyama H and Hanaoka K: Role for cyclooxygenase 2 in the development and maintenance of neuropathic pain and spinal glial activation. Anesthesiology. 103:837–844. 2005.PubMed/NCBI View Article : Google Scholar
22	Karantza MV, Mittelman SD, Dorey F, Samie S, Kaiserman K, Halvorson M and Kaufman FR: Relationship of highly sensitive C-reactive protein and lipid levels in adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 9:122–126. 2008.PubMed/NCBI View Article : Google Scholar
23	Vezzani A: Inflammation and epilepsy. Epilepsy Curr. 5:1–6. 2005.PubMed/NCBI View Article : Google Scholar
24	Cantor DS and Chabot R: QEEG studies in the assessment and treatment of childhood disorders. Clin EEG Neurosci. 40:113–121. 2009.PubMed/NCBI View Article : Google Scholar
25	Porras-Kattz E, Harmony T, Ricardo-Garcell J, Galán L, Fernández T, Prado-Alcalá R, Avecilla-Ramírez G, Sánchez-Moreno L, Barrera-Reséndiz J, Corsi-Cabrera M, et al: Magnesium valproate in learning disabled children with interictal paroxysmal EEG patterns: Preliminary report. Neurosci Lett. 492:99–104. 2011.PubMed/NCBI View Article : Google Scholar